Skinvisible, Inc.

SKVI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $20.0K $20.0K $20.0K $279.3K $663.4K $152.6K $42.1K $69.3K
Cost of Revenue $4.8K $3.3K $17.6K $20.7K
Gross Profit $20.0K $20.0K $20.0K $274.5K $660.1K $275.6K $25.6K $48.6K
Gross Margin 100.0% 100.0% 100.0% 98.3% 99.5% 180.5% 60.9% 70.1%
Operating Expenses
Research & Development
SG&A Expense $496.1K $589.2K $491.6K $494.2K $454.1K $497.2K $525.8K $607.6K
Operating Income $-496.3K $-589.6K $-490.4K $-238.4K $188.1K $-253.7K $-539.8K $-597.9K
Operating Margin -2,481.6% -2,947.9% -2,451.9% -85.4% 28.3% -166.2% -1,283.2% -862.2%
Interest Expense $572.2K $669.4K $1.9M $1.2M $1.2M $1.2M $1.0M $1.0M
Pretax Income $-1.4M $-1.7M
Income Tax Expense
Net Income $-1.1M $-565.7K $-2.4M $-1.2M $-1.1M $-1.4M $-1.7M $158.3K
Net Margin -5,320.2% -2,828.3% -11,912.2% -438.6% -161.7% -948.4% -4,046.3% 228.3%
EPS (Basic) $-0.20 $-0.11 $-0.52 $-0.27 $-0.24 $-0.32 $-0.59 $0.01
EPS (Diluted) $-0.11 $-0.52 $-0.27 $-0.24 $-0.32 $-0.59 $0.01
Shares Outstanding (Basic) 5.4M 5.1M 4.5M 4.5M 4.5M 4.5M 2.9M 2.9M
Shares Outstanding (Diluted) 5.4M 5.1M 4.5M 4.5M 4.5M 4.5M 2.9M 30.1M
Dividends Per Share
← Newer Page 1 of 2 Older →